Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Chemoradiotherapy treatment of adults with locally advanced cervical cancer who have not received prior definitive therapy: SMC2829

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Pembrolizumab in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of International Federation of Gynaecology and Obstetrics (FIGO) 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy is being assessed for use by NHSScotland (SMC2829).

The aim of this work was to capture real-world evidence from Scotland on the use of Systemic Anti-Cancer Therapy (SACT) prescribed alongside concurrent radiotherapy for the treatment of cervical cancer, hereby referred to as chemoradiotherapy. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2829, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients who received chemoradiotherapy for the treatment of locally advanced cervical cancer.
• Describe the baseline characteristics of patients who received chemoradiotherapy for the treatment of locally advanced cervical cancer.